Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cortelezzi, A
Right arrow Articles by Lambertenghi Deliliers, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cortelezzi, A
Right arrow Articles by Lambertenghi Deliliers, G
Haematologica, Vol 90, Issue 3, 410-412
Copyright © 2005 by Ferrata Storti Foundation

Clinical Trial

A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia

A Cortelezzi, MC Pasquini, B Sarina, G Bertani, F Grifoni, M Colombi, and G Lambertenghi Deliliers

Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.


This article has been cited by other articles:


Home page
 ASH Education BookHome page
V. A. Morrison
Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology, January 1, 2007; 2007(1): 332 - 338.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood, February 15, 2006; 107(4): 1276 - 1283.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.